Ixazomib
Common brands: Ninlaro, Revlimid, Ozurdex, Hemady, Maxidex
Top reporter: Takeda Pharmaceuticals America, Inc.
Thalidomide Analog [EPC]Corticosteroid [EPC]Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
28,443
Total Reports
12,086
Serious Reports
5,260
Death Reports
30
Reported Reactions
Death Report Ratio: High (18.49%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Ixazomib.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PLASMA CELL MYELOMA | 3,636 | |
| 2 | DEATH | 3,301 | |
| 3 | DIARRHOEA | 3,141 | |
| 4 | OFF LABEL USE | 2,950 | |
| 5 | PNEUMONIA | 1,923 | |
| 6 | FATIGUE | 1,910 | |
| 7 | NAUSEA | 1,835 | |
| 8 | NEUROPATHY PERIPHERAL | 1,443 | |
| 9 | VOMITING | 1,103 | |
| 10 | RASH | 1,083 | |
| 11 | THROMBOCYTOPENIA | 1,044 | |
| 12 | PLATELET COUNT DECREASED | 994 | |
| 13 | CONSTIPATION | 963 | |
| 14 | ASTHENIA | 909 | |
| 15 | PRODUCT DOSE OMISSION ISSUE | 795 | |
| 16 | DRUG INEFFECTIVE | 792 | |
| 17 | MALAISE | 732 | |
| 18 | PYREXIA | 717 | |
| 19 | PERIPHERAL SWELLING | 700 | |
| 20 | BACK PAIN | 671 | |
| 21 | NEUTROPENIA | 671 | |
| 22 | FALL | 649 | |
| 23 | ANAEMIA | 638 | |
| 24 | DYSPNOEA | 634 | |
| 25 | COVID-19 | 607 | |
| 26 | WHITE BLOOD CELL COUNT DECREASED | 573 | |
| 27 | DIZZINESS | 567 | |
| 28 | DECREASED APPETITE | 563 | |
| 29 | NO ADVERSE EVENT | 523 | |
| 30 | PAIN | 461 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.